Social Media Mocks Scientist Mariano Barbacid's Face – While He Just Cured Pancreatic Cancer in Mice

As headlines around the world reported a rare breakthrough against one of the deadliest cancers known to medicine, an uglier parallel story began unfolding online.

Recently, researchers at Spain's National Cancer Research Centre (CNIO) published a study in Proceedings of the National Academy of Sciences detailing what many scientists called an extraordinary preclinical result: a combination therapy that fully eliminated aggressive pancreatic tumours in mice.

The work was led by veteran cancer biologist Mariano Barbacid, whose career spans more than four decades and includes the discovery of the first human oncogene.

Yet as images of Barbacid circulated alongside news of the study, parts of social media fixated not on the science but on his face.

A Rare Breakthrough Against a Deadly Cancer

Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with a five-year survival rate hovering around 12 per cent in humans. Nearly 90 per cent of cases are driven by mutations in the KRAS gene, a target that has long frustrated researchers due to drug resistance and rapid tumour adaptation.

According to reports, Barbacid's team tested a three-drug combination designed to block several cancer-driving pathways at once. The therapy paired a KRAS G12D inhibitor (daraxonrasib) with afatinib, which targets EGFR and HER2 signalling, and SD36, a compound that degrades the STAT3 protein linked to tumour survival.

Across multiple mouse models—including genetically engineered mice and patient-derived tumours—the results were striking. Tumours regressed completely, showed no signs of relapse for more than 200 days, and did not develop resistance.

Toxicity was minimal, a key hurdle in pancreatic cancer research. However, independent scientists urged caution, stressing that the findings are preclinical and years away from human trials.

Fixation With Barbacid's Birthmark

Coverage of the study spread rapidly through international media, scientific institutions and cancer advocates highlighted the work as a potential blueprint for future treatment strategies.

But as Barbacid's photo circulated alongside celebratory headlines, an ugly side of the internet came to the surface, and cruel comments began appearing on platforms including X, Instagram, TikTok, and Facebook.

Users mocked a visible vascular birthmark on the left side of Barbacid's face, which is a benign congenital condition present since birth. Remarks such as, 'He cured cancer but not his own face,' and 'What's wrong with his face?'

The fixation stood in sharp contrast to the gravity of the research itself.

Backlash Against the Backlash

The mockery did not go unanswered. Replies and quote posts quickly filled with condemnation, with many users calling the comments emblematic of social media's worst instincts.

'This man just made history against one of the deadliest cancers and people are mocking a birthmark?' one response read. Another wrote, 'We're talking about pancreatic cancer—and this is what people choose to focus on?'

Several users pointed out that some of the most viral images appeared altered or misleading, amplifying the mark beyond what appears in verified photographs.

Mariano Barbacid's Legacy and Impact

Barbacid is not a newcomer to medical research. Born in Madrid in 1949, he trained at the US National Cancer Institute and rose to prominence in the early 1980s after isolating the first human oncogene, HRAS, a discovery that helped shape modern cancer biology.

For decades, his work has focused on KRAS signalling, a pathway many researchers once deemed 'undruggable.' His current role as head of CNIO's Experimental Oncology Group places him at the centre of Europe's cancer research ecosystem.

Those familiar with his career note that the pancreatic cancer study fits into a long-term scientific arc, rather than representing a sudden or isolated success

Despite some social media posts loosely describing the findings as a 'cure,' Barbacid and CNIO have been careful to temper expectations. The study was conducted entirely in mice, and translating such results to humans often takes many years, if it succeeds at all.